No Results

No Results


Nephrostomy is a term used to describe a passageway maintained by a tube, stent, or catheter that perforates the skin, passes through the body wall and renal parenchyma, and terminates in the renal pelvis or a calyx.

The nephrostomy has multiple functions but is used most frequently to provide urinary drainage when the ureter is obstructed and retrograde access is inadvisable or impossible. A nephrostomy can also be used to gain access to the upper urinary tract for various antegrade endourologic procedures, such as intracorporeal lithotripsy, chemical stone dissolution, antegrade radiologic studies of the ureter, and double-J stent placement.

Nephrostomy has several other functions, including the following:

To remove or dissolve renal calculi

To obtain direct access to the upper urinary tract for various endourologic procedures

To diagnose ureteral obstruction, filling defects, and anomalies via antegrade radiography

To deliver chemotherapeutic agents to the renal collecting system

To provide prophylaxis after resection for local chemotherapy in patients with tumors of the renal pelvis

An assessment of blood serum creatinine can be used to help evaluate obstruction and dilatation of the renal pelvis. Elevated levels indicate that the renal pelvis obstruction is related to kidney function. However, in all patients, nephrotoxic substances should be excluded as a source of renal failure. A renal scan is helpful in borderline cases (ie, when the renal pelvis is normal or minimally dilated and the creatinine level is slightly elevated).

To determine whether an obstruction is new or old, the patient’s history is essential. Old radiographs or sonograms can also be helpful. Most commonly, acute obstruction is caused by renal stones, whereas chronic obstruction is caused by renal or ureteral tumors and postoperative and radiation strictures of the ureter. A prior instance of renal failure was usually due to chronic obstruction.

The most dangerous cases of renal obstruction occur in patients who have urosepsis with renal obstruction and elevated creatinine levels. Fast renal access can be lifesaving in these patients. However, as with any procedure, the patient’s general situation and prognosis must be evaluated prior to the procedure.

Tumors, such as sarcomas, ovarian tumors, and other retroperitoneal tumors (Ormond disease, intraperitoneal tumors), can compress the ureter. A nephrostomy may be required in all of these cases. Do not attempt retrograde access if a tumor spill or vascular lesion is likely to develop. Depending on the anatomical situation of the stricture, patients with ureteral strictures after vascular surgery, eg, for an aortofemoral bypass, should undergo nephrostomy placement.

Anatomical anomalies, such as ureteropelvic junction (UPJ) obstruction, can create difficulty in retrograde access. Tumors or strictures that completely compress the ureter complicate or prevent retrograde access to the kidney. Passing a stent or guidewire antegrade rather than retrograde can be easier, as cystoscopy is not needed for antegrade access to the ureter.

Flexible antegrade pyeloureteroscopy can be performed through the nephrostomy when retrograde access to the ureter or kidney is not possible because of anatomic anomalies, tumors, or strictures.

In 1912, Hugh Hampton Young passed a pediatric cystoscope percutaneously into a massively hydronephrotic kidney. Willard Goodwin, MD, described percutaneous access and nephrostomies in 1955. [1] In 1976, Fernström and Johansson performed a percutaneous nephrostomy specifically to remove a kidney stone. [2] In 1979, Smith and colleagues, from the University of Minnesota, began to remove stones in the renal pelvis and the ureter through percutaneous nephrostomy tracts. Nephrostomy tube placement is shown in the image below. In 1981, Alken and colleagues, who were working in Germany, removed stones through matured percutaneous tracts. [3]

For more information on stone disease, see Medscape’s Stone Disease Resource Center.

Nephrostomy involves creating an opening into the kidney to maintain temporary or permanent urinary drainage. The collecting system of the kidney is punctured percutaneously with a needle under fluoroscopic, ultrasonographic, or CT guidance. The needle is passed through the skin, subcutaneous tissue, external and internal muscle layers, and the renal parenchyma to reach the collecting system. When the needle has entered the renal collecting system, a guidewire is passed through the needle into the kidney and possibly down the ureter. Over the guidewire, various dilators can be used to establish and enlarge the nephrostomy tract, which is then maintained by a tube.

Alternatively, a nephrostomy tube can be placed during open surgery. In this procedure, a tube is placed into the renal pelvis, perforating the renal parenchyma and puncturing the flank musculature, subcutaneous tissues, and skin to create a direct passage between the renal collecting system and the external environment.

Anesthetic agents can be more hazardous in patients with overt renal shock. Therefore, performing the nephrostomy under local anesthesia is especially important when the procedure is potentially lifesaving.

Symptoms of upper urinary tract obstruction can include flank or abdominal pain, nausea, vomiting, fever, or mild-to-severe urosepsis, including septic shock. Patients with calculi may be asymptomatic.

Percutaneous nephrostomy is occasionally essential, if not lifesaving, in the treatment of acute or chronic upper urinary tract obstruction. It is the first step in obtaining antegrade access to the kidney for various procedures. Specific indications for percutaneous nephrostomy include the following:

Acute or chronic upper urinary tract obstruction in which access to the kidney is impossible from the lower urinary tract because of stones, infections, tumors, or anatomic anomalies, especially when a double-J stent cannot be placed through the ureter because of above-mentioned circumstances

When a patient’s creatinine level is rising above the reference range and the urine cannot be drained through the ureter

Renal pelvis disorders (eg, UPJ obstruction, horseshoe kidneys, ureter duplex, ureter fissures, double renal collecting systems)

Hydronephrosis in renal transplant allografts: When dilatation of the renal pelvis affects kidney function to the extent that double-J stent placement is difficult or impossible, percutaneous nephrostomy may be an easier option.

Treatment of staghorn calculi and large or lower-pole kidney stones (when a percutaneous nephrolithotomy [PCN] is likely to be followed because of the stone burden and an extracorporeal shockwave lithotripsy [ESWL] is less likely to be successful)

Contraindications to ESWL (ie, size of patient): Most ESWL units have a weight limit of 140 kg (approximately 300 lb).

Body habitus that prevents ESWL (eg, contractures): Disabled patients occasionally cannot be positioned on an ESWL unit in a prone or supine position.

Stones or tumors associated with distal obstruction or a foreign body that cannot be removed through the ureter

When rapid dilation of the nephrostomy tract is required (eg, when access is needed instantly for operative procedures within the renal collecting system [for stone removal or tumor ablation])

Prolonged sequential dilatation: Gradually increasing the catheter size may be necessary when a nephrostomy tube is placed permanently for urine drainage in patients in whom a retrograde access to the kidney is impossible (eg, advanced metastatic tumors, loss of the total ureter, patients with a palliative nephrostomy tube whose cases are inoperable).

A rare indication is antegrade nephrostomy to control a ureteral lesion after ureteral trauma that cannot be fixed in a retrograde fashion in a nonobstructed kidney. This can occur with a completely dissected ureter after gynecological, surgical, or urological procedures discovered after the procedure. Most likely, a urinoma has developed around the dissected ureter, with the kidney itself not being obstructed but in being need for a nephrostomy.

In an emergency situation a nephrostomy may always be mandatory.

The kidneys are paired retroperitoneal organs below the diaphragm—below the liver on the right and below the spleen on the left. The kidney is located at the level of the 10th to the 12th ribs. The principal areas of the kidney include the renal cortex and medulla, renal pelvis, renal papillae, renal pyramids, ureter, renal artery, and renal vein. Renal anatomy is shown below.

A fat capsule, the Gerota fascia, surrounds the kidney. The Brödel line also has historical interest. The minor renal calyces come together to the major renal calyces and make up the renal pelvis. The following organs supply blood to the kidney, in descending order: renal artery, interlobar artery, arcuate artery, intralobular artery, afferent arterioles, and glomerulus. All arterioles end arteries without communication, which is important for a possible embolization.

See the list below:

Bleeding diathesis (eg, hemophilia, thrombocytopenia) and uncontrolled hypertension

Anticoagulant use (eg, aspirin [relative contraindication], heparin, warfarin)

Goodwin WE, Casey WC, Woolf W. Percutaneous trocar (needle) nephrostomy in hydronephrosis. J Am Med Assoc. 1955 Mar 12. 157(11):891-4. [Medline].

Fernström I, Johansson B. Percutaneous pyelolithotomy. A new extraction technique. Scand J Urol Nephrol. 1976. 10(3):257-9. [Medline].

Alken P, Hutschenreiter G, Gunther R, et al. Percutaneous stone manipulation. J Urol. 1981 Apr. 125(4):463-6. [Medline].

Parikh GP, Shah VR, Modi MP, Chauhan NC. The analgesic efficacy of peritubal infiltration of 0.25% bupivacaine in percutaneous nephrolithotomy – A prospective randomized study. J Anaesthesiol Clin Pharmacol. 2011 Oct. 27(4):481-4. [Medline]. [Full Text].

Ozok HU, Sagnak L, Senturk AB, Karakoyunlu N, Topaloglu H, Ersoy H. A Comparison of Metal Telescopic Dilators and Amplatz Dilators for Nephrostomy Tract Dilation in Percutaneous Nephrolithotomy. J Endourol. 2011 Oct 14. [Medline].

Li CC, Li JR, Huang LH, Hung SW, Yang CK, Wang SS, et al. Metallic stent in the treatment of ureteral obstruction: Experience of single institute. J Chin Med Assoc. 2011 Oct. 74(10):460-3. [Medline].

Deshmukh S, Sternberg K, Hernandez N, Eisner BH. Compliance with American Urological Association Guidelines for Post-Percutaneous Nephrolithotomy Antibiotics Does Not Appear to Increase Rates of Infection. J Urol. 2015 Oct. 194 (4):992-6. [Medline].

Viers BR, Cockerill PA, Mehta RA, Bergstralh EJ, Krambeck AE. Extended antimicrobial use in patients undergoing percutaneous nephrolithotomy and associated antibiotic related complications. J Urol. 2014 Dec. 192 (6):1667-72. [Medline].

Bayne D, Taylor ER, Hampson L, Chi T, Stoller ML. Determinants of nephrostomy tube dislodgment after percutaneous nephrolithotomy. J Endourol. 2015 Mar. 29 (3):289-92. [Medline].

Biyani CS, O’Connor JP, Browning AJ. Laparoscopic removal of retained nephrostomy tubing. J Urol. 2003 Sep. 170(3):916-7. [Medline].

Bloom DA, Morgan RJ, Scardino PL. Thomas Hillier and percutaneous nephrostomy. Urology. 1989 Apr. 33(4):346-50. [Medline].

Carson CC, Little N. The absolute and relative contraindications to ESWL. Problems in Urology. Philadelphia, Pa: JB Lippincott Co; 1987. Vol 1: 580.

Clayman RV, Kavoussi LR. Endosurgical techniques for noncalculous disease. Campbell’s Urology. 7th ed. Philadelphia, Pa: WB Saunders Co; 1992. 2235-45.

Coleman CC, Kimura Y, Reddy P. Complications of nephrostolithotomy. Sem Intervent Radiol. 1984. 1:24.

Grasso M, Loisides P, Beaghler M, et al. The case for primary endoscopic management of upper urinary tract calculi: I. A critical review of 121 extracorporeal shock-wave lithotripsy failures. Urology. 1995 Mar. 45(3):363-71. [Medline].

Grasso MG, Taylor F. Techniques for percutaneous renal access. Sosa RE, Albala DM, eds. Textbook of Endourology. Philadelphia, Pa: WB Saunders Co; 1996.

Kaskarelis IS, Papadaki MG, Malliaraki NE, et al. Complications of percutaneous nephrostomy, percutaneous insertion of ureteral endoprosthesis, and replacement procedures. Cardiovasc Intervent Radiol. 2001 Jul-Aug. 24(4):224-8. [Medline].

Kavanagh DO, Fanning N, Heffernan E, et al. Management of gestational nephrolithiasis in the presence of a bicornuate uterus and pelvic kidney. Int J Urol. 2005 Feb. 12(2):211-3. [Medline].

Kukreja R, Desai M, Patel S, et al. Factors affecting blood loss during percutaneous nephrolithotomy: prospective study. J Endourol. 2004 Oct. 18(8):715-22. [Medline].

Lam HS, Lingeman JE, Mosbaugh PG, et al. Evolution of the technique of combination therapy for staghorn calculi: a decreasing role for extracorporeal shock wave lithotripsy. J Urol. 1992 Sep. 148(3 Pt 2):1058-62. [Medline].

LeRoy AJ, Williams HJ Jr, Bender CE, et al. Colon perforation following percutaneous nephrostomy and renal calculus removal. Radiology. 1985 Apr. 155(1):83-5. [Medline].

Little B, Ho KJ, Gawley S, et al. Use of nephrostomy tubes in ureteric obstruction from incurable malignancy. Int J Clin Pract. 2003 Apr. 57(3):180-1. [Medline].

Mariappan P, Smith G, Bariol SV, et al. Stone and pelvic urine culture and sensitivity are better than bladder urine as predictors of urosepsis following percutaneous nephrolithotomy: a prospective clinical study. J Urol. 2005 May. 173(5):1610-4. [Medline].

Motola JA, Smith AD. Therapeutic options for the management of upper tract calculi. Urol Clin North Am. 1990 Feb. 17(1):191-206. [Medline].

Picus D, Weyman PJ, Clayman RV, et al. Intercostal-space nephrostomy for percutaneous stone removal. AJR Am J Roentgenol. 1986 Aug. 147(2):393-7. [Medline].

Segura JW. Percutaneous management. Campbell’s Urology. 7th ed. Philadelphia, Pa: WB Saunders; 1992. 2183-94.

Segura JW, Preminger GM, Assimos DG, et al. Nephrolithiasis Clinical Guidelines Panel summary report on the management of staghorn calculi. The American Urological Association Nephrolithiasis Clinical Guidelines Panel. J Urol. 1994 Jun. 151(6):1648-51. [Medline].

Smith AD. Management of iatrogenic ureteral strictures after urological procedures. J Urol. 1988 Dec. 140(6):1372-4. [Medline].

Strohmaier WL, Giese A. Ex vivo training model for percutaneous renal surgery. Urol Res. 2005 Jun. 33(3):191-3. [Medline].

Tanaka T, Yanase M, Takatsuka K. Clinical course in patients with percutaneous nephrostomy for hydronephrosis associated with advanced cancer. Hinyokika Kiyo. 2004 Jul. 50(7):457-62. [Medline].

Whitaker RH. An evaluation of 170 diagnostic pressure flow studies of the upper urinary tract. J Urol. 1979 May. 121(5):602-4. [Medline].

Zagoria RJ, Dyer RB. Do’s and don’t’s of percutaneous nephrostomy. Acad Radiol. 1999 Jun. 6(6):370-7. [Medline].

Shellikeri S, Daulton R, Sertic M, Connolly B, Hogan M, Marshalleck F, et al. Pediatric Percutaneous Nephrostomy: A Multicenter Experience. J Vasc Interv Radiol. 2018 Mar. 29 (3):328-334. [Medline].

Stefan H Hautmann, MD, PhD Professor of Urology, Director, Department of Urology and Pediatric Urology, Luedenscheid Hospital, Academic Hospital of the University of Bonn, Germany

Disclosure: Nothing to disclose.

Raymond J Leveillee, MD, FRCS(Glasg) Professor of Clinical Urology, Radiology and Biomedical Engineering, Department of Urology, University of Miami Miller School of Medicine; Chief, Division of Endourology/Laparoscopy and Minimally Invasive Surgery, Department of Urology, Jackson Memorial Hospital

Raymond J Leveillee, MD, FRCS(Glasg) is a member of the following medical societies: American Urological Association, Endourological Society, Sigma Xi, Society of Laparoendoscopic Surgeons

Disclosure: Received honoraria from ACMI/Gyrus for speaking and teaching; Received honoraria from Boston Scientific for speaking and teaching; Received honoraria from Applied Medical for speaking and teaching; Received honoraria from Intuitive Surgical for speaking and teaching; Received grant/research funds from Intio for other.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Shlomo Raz, MD Professor, Department of Surgery, Division of Urology, University of California, Los Angeles, David Geffen School of Medicine

Shlomo Raz, MD is a member of the following medical societies: American College of Surgeons, American Medical Association, American Urological Association, California Medical Association

Disclosure: Nothing to disclose.

Bradley Fields Schwartz, DO, FACS Professor of Urology, Director, Center for Laparoscopy and Endourology, Department of Surgery, Southern Illinois University School of Medicine

Bradley Fields Schwartz, DO, FACS is a member of the following medical societies: American College of Surgeons, American Urological Association, Association of Military Osteopathic Physicians and Surgeons, Endourological Society, Society of Laparoendoscopic Surgeons, Society of University Urologists

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Cook Medical; Olympus.

Raymond R Rackley, MD Professor of Surgery, Cleveland Clinic Lerner College of Medicine; Staff Physician, Center for Neurourology, Female Pelvic Health and Female Reconstructive Surgery, Glickman Urological Institute, Cleveland Clinic, Beachwood Family Health Center, and Willoughby Hills Family Health Center; Director, The Urothelial Biology Laboratory, Lerner Research Institute, Cleveland Clinic

Raymond R Rackley, MD is a member of the following medical societies: American Urological Association

Disclosure: Nothing to disclose.


Research & References of Nephrostomy|A&C Accounting And Tax Services